Last reviewed 2026-04-20 · How we verify

Meprothixol (MEPROTIXOL)

Phase 2 active Small molecule

Meprothixol (generic name: MEPROTIXOL) is a meprotixol drug. It is currently in Phase 2 development.

Meprothixol is a small molecule that works by interacting with a specific target in the body, but its exact mechanism is unknown.

Meprothixol is a small molecule drug of the meprotixol class, but its target and mechanism of action are unknown. Its commercial status, including FDA approval and patent status, is also unclear. As a result, there is limited information available on its approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to understand the clinical utility and safety profile of meprothixol. Its development and ownership history are also unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MEPROTIXOL
Drug class	meprotixol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and meprothixol is a key that fits into one of those locks. When it binds to the lock, it can either turn the lock open or closed, depending on the type of lock and the key's shape. However, since meprothixol's target is unknown, we can't say exactly how it works or what kind of lock it fits into.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Meprothixol CI brief — competitive landscape report
Meprothixol updates RSS · CI watch RSS

Frequently asked questions about Meprothixol

What is Meprothixol?

Meprothixol (MEPROTIXOL) is a meprotixol drug.

How does Meprothixol work?

Meprothixol is a small molecule that works by interacting with a specific target in the body, but its exact mechanism is unknown.

What is the generic name of Meprothixol?

MEPROTIXOL is the generic (nonproprietary) name of Meprothixol.

What drug class is Meprothixol in?

Meprothixol belongs to the meprotixol class. See all meprotixol drugs at /class/meprotixol.

What development phase is Meprothixol in?

Meprothixol is in Phase 2.

Drug class: All meprotixol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing